Loading clinical trials...
Loading clinical trials...
The purpose of this study is to evaluate the safety and tolerability of NMS-1286937, a polo-like-kinase 1 inhibitor, in patients with advanced metastatic solid tumor.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Nerviano Medical Sciences
NCT06248411 · Advanced or Metastatic Solid Tumors
NCT06307795 · Locally Advanced or Metastatic Solid Tumors
NCT06716138 · Locally Advanced or Metastatic Solid Tumors Harboring a ROS1 or NTRK Alteration
NCT05753722 · Advanced or Metastatic Solid Tumors, Non Small Cell Lung Cancer, and more
NCT05581004 · Locally Advanced or Metastatic Solid Tumors, NSCLC, and more
Arizona TGen Clinical Research Services at Scottsdale Heathcare
Scottsdale, Arizona
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions